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DOI 10.1016/j.immuni.2010.01.008O’Brien et al. (2010) commented on twogd
T cell papers recently published in Immu-
nity (Martin et al., 2009; Sutton et al.,
2009) and raise a number of questions.
We are responding to those that apply to
our paper (Martin et al., 2009).
The main focus of our paper was the
demonstration that a subset of gd T cells
(CCR6+) shares characteristic features
with T helper 17 (Th17) cells and that
these can respond to specific Toll-like
receptor (TLR) ligands with the production
of interleukin-17 (IL-17) even without the
interaction with antigen-presenting cells
providing IL-23. Nowhere in our paper
do we claim that we are the first to show
gd T cells can produce IL-17 without
deliberate stimulation via the TLR. In fact
we say: ‘‘This does not preclude a role of
TCR and our studies do not allow the
conclusion that TLR triggers act in isola-
tion.’’ We are aware that a wide range of
signals, including stress-induced signals
could activate the TCR on gd T cells so
that it is virtually impossible to exclude
TCR triggering. As mentioned in our
paper, IL-17-producing gd T cells have
an activated phenotype already when
isolated ex vivo, suggesting prior TCR-
mediated activation. We also clearly state
in the Discussion the following: ‘‘For the
in vitro experiments showing functional
effects of TLR ligands, we FACS sorted
gd T cells by using antibodies directed
against the T cell receptor that most likely
causes activation, and the injection of
pure TLR ligands in vivo cannot exclude
simultaneous TCR triggers by potential
endogenous ligands.’’
We have cited the paper by Shibata
et al. (2007), which is relevant regarding
IL-17 production by gd T cells, whereas
the paper by Cheng et al. (2008) does
not really focus on this issue and was
therefore not included.2 Immunity 32, January 29, 2010 ª2010 ElsevRegarding the identification of the IL-17
producing subset, we agree with O’Brien
et al. that there are differences in repre-
sentation of Vg2 (called Vg4 by Heilig
and Tonegawa, 1986) and Vg1 subsets
after intraperitoneal versus subcutaneous
injection. However, these are subtle alter-
ations in ratios and both subsets contain
IL-17 producers. The confusion with
different nomenclatures in the gd T cell
field does not help, but we are certainly
not comparing oranges with apples. First,
we show in our paper (Figure 1D in Martin
et al., 2009) the distribution of IL-17
producers in peripheral lymph nodes
from unimmunized mice—there is no
CFA injection involved here. Most IL-17
producers in the lymph nodes are Vg2
(Vg4 in Tonegawa nomenclature) and
a few are Vg1. There is a subset of
Vg1.2 (probably those that are called
Vg4Vg1 by O’Brien et al.) for which
there is no commercially available anti-
body—this accounts for the 25%
missing proportion of cells in Figure 1D
(Martin et al., 2009). None of the other
Vg subsets are found in substantial
numbers in peripheral lymphoid organs.
We have not shown Vg allocations for
immunized mice in this paper, but we
find that draining lymph nodes from CFA
immunized mice analyzed between 3 hr
and 48 hr afterward are 80% Vg2 (the
proportional representation of different
Vg subsets is not stated in the Figure S1
shown by O’Brien et al., 2010).
PEC from mice immunized with heat-
killed mycobacteria (we are not autho-
rized to inject CFA i.p.) analyzed 12 hr
later have a somewhat reduced propor-
tion of Vg2 cells (60% instead of 80% as
in resting lymph nodes from unimmunized
mice), but the remainder expresses IL-17
and the associated program to the same
extent. As we state in our paper:ier Inc.‘‘Although CCR6+CD44+ gd T cells, the
majority of which are IL-17 producers,
were not restricted to a unique gd T cell
subpopulation, the majority of IL-17+ gd
T cells expressed the T cell receptor chain
Vg2.’’ This remains correct even if this
majority may be somewhat less promi-
nent after immunization. Furthermore,
O’Brien et al. (2010) claim that we are
looking at Vg6 T cells in the peritoneal
cavity—this was not the case because
we were focusing on CCR6+ cells and
did not mention Vg subsets anywhere
other than Figure 1D in our paper. Vg6
cells, called Vg4 in the Garman nomencla-
ture that we have used (Garman et al.,
1986), are the prominent subset found in
the lung and are not present in the perito-
neal cavity. All in all, the objections raised
by O’Brien et al. regarding our paper
seem to be based on a number of misun-
derstandings.REFERENCES
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